PT-141
What We've Seen in Practice, and What the Research Says
PT-141, known generically as bremelanotide and sold as Vyleesi, is unusual on this page for one reason: it is actually FDA-approved. Most peptides we write about are investigational, but PT-141 cleared full trials and reached the market in 2019 as a treatment for low sexual desire in women. It works in a way that sets it apart from the familiar erectile-dysfunction pills, acting on the brain's desire circuits rather than on blood flow.
At the same time, the approval is narrow, and the details matter as much as the headline. The measured benefit is modest and has been debated in the research, and in our own experience PT-141 has been useful but finicky. This page lays out both what the drug can do and where it falls short, so you can weigh it for yourself.
.svg)
What we've seen in practice
Dr. Koniver's take on PT-141 is honest and a little mixed, and we think that is the useful version. He describes it as a peptide that can help men with erectile dysfunction and women with libido, working through the nervous system rather than the circulation. The interest is real, and plenty of patients want to try it. But he is candid that the results are inconsistent and that it is not always our first reach.
The main problem is that PT-141 has a narrow therapeutic window and is genuinely hard to dose. Give a little too much and it tends to cause nausea; give too little and it does not seem to do much. As a standalone injection, that finickiness, plus the nausea, is enough that we do not lean on it heavily.
Where it has found a more comfortable place is as a nasal spray, and specifically as one part of a combination we use for desire and bonding, alongside oxytocin and Selank. In that nasal form it tends to be better tolerated than the injection, and Dr. Koniver describes it as a nice boost for the right person before intimacy. His overall framing is measured: these peptides are very safe, this one is reasonable to try, and it does not always work.
PT-141 at a glance
A synthetic cyclic peptide (bremelanotide) that increases sexual desire by acting on the brain, approved as Vyleesi [6]
.svg)
Low sexual desire in women (the approved use); off-label for male erectile dysfunction and for libido more broadly [1]
.svg)
FDA-approved with Phase 3 trials behind it, though the measured effect is modest and has been debated [1, 4]
.svg)
By subcutaneous injection (the approved route) or, in our practice, as a nasal spray, often in a combination
.svg)
A cyclic heptapeptide, formula C50H68N14O10, about 1,025 g/mol [6]
FDA-approved (Vyleesi, 2019) for premenopausal women with low desire; not named on the WADA prohibited list
Useful but finicky; hard to dose, can cause nausea, and mainly used by us as part of a nasal combination. See what we have seen in practice above
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH: seven residues joined in a ring. Draw it as a cyclic ring, not a straight chain.
Where PT-141 comes from
PT-141 has an unusual origin story. It began with Melanotan, a peptide developed to stimulate the skin's tanning response. During that research, scientists noticed a side effect: it seemed to increase sexual arousal. Rather than discard that observation, they engineered a related peptide that kept the arousal effect while reducing the tanning activity, and that peptide became PT-141, or bremelanotide.
Because of that lineage, PT-141 is a melanocortin peptide, a cousin of the body's own melanocyte-stimulating hormone. It was first pursued for erectile dysfunction in the early 2000s, and later found its regulatory home in treating low sexual desire in women. The tanning-peptide heritage is not just trivia, either: at high or repeated doses PT-141 can still darken the skin, which is one of the reasons it has to be dosed carefully.
Melanotan
PT-141 (bremelanotide)
How PT-141 works
PT-141 works through the brain, and understanding that is the key to understanding both its appeal and its side effects.
.svg)
PT-141 stimulates melanocortin receptors, chiefly MC3R and MC4R, in the hypothalamus and nearby regions that govern sexual motivation, turning up the neural signaling behind desire.[3]
.svg)
The common erectile-dysfunction pills work on blood flow. PT-141 instead acts on the nervous system, upstream of the physical response, which is why it can affect desire itself.[3]
.svg)
Because melanocortin receptors sit in many systems, activating them affects more than desire. That breadth is part of why nausea, flushing, and blood-pressure changes show up.[3]
Brain / desire circuit (neurogenic)
Blood flow (vascular)
A genuinely approved peptide, with an honest limit on how large the benefit is [1,4].
What the research shows
Here PT-141 stands apart from the research peptides in this directory, and we want to give it full credit while staying even-handed.
PT-141, as bremelanotide, went through genuine Phase 3 randomized controlled trials and was approved by the FDA in 2019. The pivotal studies, known as the RECONNECT trials, enrolled roughly twelve hundred premenopausal women with hypoactive sexual desire disorder and showed a statistically significant improvement in desire and a reduction in the distress that goes with it, compared with placebo. Long-term safety was studied in an open-label extension. This is a real, regulator-grade evidence base, and it is why PT-141 is an approved medicine rather than an experimental one.
Female low desire (HSDD)
Phase 3 randomized trials (RECONNECT)
A real but modest improvement in desire and related distress vs placebo
FDA-approved use [1]
How big is the benefit
Independent critical review
The average effect is small and its everyday importance is debated
An honest limit on expectations [4]
Male erectile dysfunction
Earlier, smaller studies
Signal of benefit through a central mechanism
Off-label; not FDA-approved
Our clinical experience
Selective use, mainly nasal
Useful for some, finicky to dose, mixed feedback
Clinical observation, not a trial
How strong is the evidence
This is the highest-evidence page in the directory: a genuine FDA-approved, Phase 3 top tier (green). The honesty is in how large the benefit is, not in the quality of the trials.
PT-141 has an established safety profile from its clinical trials, and in a general sense it is well characterized and, as Dr. Koniver puts it, safe to try. But it has a distinctive side-effect pattern that shapes how it is used.
The signature side effect is nausea, and it is dose-related: the higher the dose, the more likely it is, which is the main reason the therapeutic window is narrow and the injection can be hard to tolerate.
Facial flushing, headache, and transient changes in blood pressure can also occur, and at high or repeated doses the melanocortin activity can darken the skin. Because of the blood-pressure effects, we are cautious in anyone with uncontrolled high blood pressure or unstable cardiovascular disease. We avoid it in pregnancy and breastfeeding. As with everything we offer, it belongs under physician supervision, and part of using it well is respecting the dose.
Regulatory status
Regulatory information current as of 12 August 2026. This is a summary, not legal or medical advice, and status can change.
International
Approval and review status vary by region and should be verified.
United States
FDA-APPROVED
Approved as Vyleesi (bremelanotide) in June 2019 for hypoactive sexual desire disorder in premenopausal women. A full approval, which is uncommon for a peptide. Scope is narrow, though: use for men, for erectile dysfunction, or for general libido is off-label. [5]
Sport (WADA)
Not listed
Not named on the WADA prohibited list, and as a brain-acting melanocortin peptide it does not fall under the hormone or growth-factor categories. Athletes should still confirm current status with their governing body.
Everywhere else
Availability and quality vary by source and jurisdiction.
Regulatory information current as of 12 August 2026. Verify status at publication.
PT-141, answered plainly
A synthetic peptide, generically called bremelanotide and sold as Vyleesi, that increases sexual desire by acting on the brain's melanocortin receptors. It is FDA-approved for low sexual desire in premenopausal women [6].
Those pills work on blood flow. PT-141 works on the nervous system, upstream of the physical response, which is why it can affect desire itself and can sometimes help when blood-flow treatments do not [3].
It helps some people, modestly. Its trials showed a real but small benefit, and independent reviewers have debated how meaningful that is day to day. In our practice the feedback is mixed, and it is finicky to dose [4].
As an injection it can be hard to dose and can cause nausea. In a nasal form, often combined with oxytocin and Selank, it tends to be better tolerated, and that is where we have found it most useful.
It is not named on the WADA prohibited list, but anti-doping rules change, so any competing athlete should confirm current status with their governing body first.
References
- Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. PMID 31599840.
- Simon JA, Kingsberg SA, Portman D, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):909-917. PMID 31599847.
- Pfaus JG, Sadiq A, Spana C, Clayton AH. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. 2022;27(3):281-289. PMID 33455598.
- Spielmans GI, Ellefson EM. Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder. J Sex Res. 2024;61(4):540-561. PMID 36809187.
- Mayer D, Lynch SE. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. Ann Pharmacother. 2020;54(7):684-690. PMID 31893927.
- Molecular data: bremelanotide (PT-141), PubChem CID 9941379, formula C50H68N14O10, molecular weight ~1025.2 g/mol. FDA approval: Vyleesi, June 2019.
This page is for informational and educational purposes and does not constitute medical advice, diagnosis, or treatment. PT-141 (Vyleesi, bremelanotide) is FDA-approved only for hypoactive sexual desire disorder in premenopausal women; other uses, including in men and for erectile dysfunction, are off-label. Statements describing how Dr. Koniver and the Koniver Wellness team use PT-141 reflect clinical experience and judgment, which is not the same as controlled clinical evidence. Nothing here is a substitute for consultation with a qualified healthcare provider. Peptide therapy at Koniver Wellness is provided under physician supervision after appropriate screening.
INTERESTED IN PEPTIDES?
START WITH THE RIGHT QUESTIONS.
Understand what peptides can and cannot do, what the evidence actually says, and whether physician-guided peptide therapy makes sense for you.